OTF & ZC

ATTORNEY DOCKET NO. 03225.0001U2 APPLICATION NO. 10/650,260 SHEET 1 OF 2

| (0 ابر | | | | | | | | • | | • | |
|---|--|--|---|-----------|-------|----------------------|-------------|-----------------------|--------|----------------------|--|
| Form PTC |)-1449 | | | | | Com | plete if Kn | own | | | |
| Form PTO-1449 U.S. DEPARTMENT OF COMMERCE | | | | | App | lication Number | | 10/650,260 | | | |
| PATENT AND TRADEMARK OFFICE | | | | | | g Date | Augi | August 27, 2003 | | | |
| | | | | | | First Named Inventor | | Poynard | | | |
| LIST OF INFORMATION CITED BY APPLICANT | | | | | | Group Art Unit | | Unassigned | | | |
| (Use as many sheets as necessary) | | | | | | · | | | | | |
| | | | | | | miner Name | Una | Unassigned | | | |
| | | | _ | | oocu | MENTS | | | | | |
| Examiner's Initials | Cite No. | Document No. | | ate | | Name | | Subcla | iss | Filing | |
| muais | <u> </u> | | | | | | | | | Date (if appropriate | |
| | *A1 | 5,935,798 | | | | Price et al. | | 35 7.23 | | | |
| | *A2 | 4,312,853 | 01720 | 5/1982 | Timp | ol | 424 | 1_ | | | |
| | | | | | | | <u> </u> | | | | |
| | FOREIGN PATENT DOCUMENTS | | | | | | | | | | |
| Examiner's Initials | Cite | Foreign Patent Docu Country Code-Number-Kin | | Dat | е | 1 1141141 | | | | nslation | |
| muais | No. | | | 0.1/0- | | | | | | Yes/No | |
| | *A3 EP 0 911 3 | | | | 999 | Tesoh Corpora | | | | | |
| | *A4 | WO 01/86304 A2 | | 11/15/2 | 2001 | Bayer Aktieng | esellschaff | | | | |
| | <u> </u> | | (A) (A) | ATENT | DO01 | IMENITO | | | | | |
| Examiner's | Cite | | | | | MENTS | | | | | |
| Initials | No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) | | | | | | | " | | |
| | *A5 | Redossa et al "A | Anoline | nrotein | Δlies | Serum and Tie | sue Mar | ker of I | iver | Fibrosis | |
| | ' | Bedossa et al., "Apolipoprotein AI is a Serum and Tissue Marker of Liver Fibrosis in Alcoholic Patients." <i>Alcohol Clin. Exp. Res.</i> 13(6):829-833 (November/December 1989) | | | | | | | | | |
| ` | | | | | | | | | | | |
| | *A6 | Gabrielli et al., "Serum laminin and type III procollagen in chronic hepatitis C. | | | | | | | | is C. | |
| | | Diagnostic value in the assessment of disease activity and fibrosis." Clin. Chim. Acta 265:21-31 (1997) | | | | | | | | | |
| | | | | | | | | | | | |
| | *A7 | Guechot et al. "Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis." Clin Chem. 42(4):558-563 (1996) | | | | | | | | | |
| | | | | | | | | nic viral | | | |
| | | | | | | | | | | | |
| | *A8 Johnston, "Special Considerations in Interpreting Liver Function Tests." A | | | | | | | | | | |
| | | Fam. Physician pp. 1-11 (April 15, 1998) www.aafp.org/afp/990415ap/2223 | | | | | | 223.html | | | |
| | *A9 | (Print Date of February 8, 2002) | | | | | | | | | |
| | 73 | Kasahara et al., "Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic | | | | | | | | | |
| | • | henatitis C. Relat | hepatitis C. Relationship to interferon response." J. Hepatol. 26(3):574-583 | | | | | | | | |
| | | (March 1997) | | F 10 1110 | | | opuloi. Z | -5(5).51 | , 5 | | |
| | *A10 Kropf et al., "Efficacy of Serum Laminin Measurement for Diagnosis of Fibrotic | | | | | | | | brotic | | |
| 12 | | Liver Diseases." Clin. Chem. 34(10):2026-2030 (1988) | | | | | | | | | |
| | *A11 | | Naveau et al., "Alpha-2-Macroglobulin and Hepatic Fibrosis, Diagnostic Interest." | | | | | | | | |
| | | Dig. Dis. Sci. 39(| 11):24 | 26-2432 | (Nov | ember 1994) | | Š | | ; | |
| | *A12 | Oberti et al., "Noninvasive Diagnosis of Hepatic Fibrosis or Cirrhosis." | | | | | | | | | |
| | | Gastroenterology | | | | | | | 7 | | |
| / | A13 | Pilette et al., "His | | | | | | | | | |
| | | analysis vs semi-quantitative scores. Comparison with serum markers." J. | | | | | | | | | |
| | *^4 | | Hepatol. 28(3):439-446 (March 1998) | | | | | | | | |
| 100 | *A14 Poynard and Bedossa, "Age and platelet count: a simple index for pred | | | | | | | | | | |
| | presence of histological lesions in patients with antibodies to hepatits C v METAVIR and CLINIVIR Cooperative Study Groups. J. Viral Hepat. 4(3) | | | | | | | | | | |
| | | 208 (May 1997) | -11 41 V II | i v Ooope | auve | Gludy Gloups. | . Viidi | i i o pat. | 4(3) | . 133* | |
| | · | | | | | | | | | | |



ATTORNEY DOCKET NO. 03225.0001U2 APPLICATION NO. 10/650,260 SHEET 2 OF 2

| | *A15 | Poynard et al., "Natural history of liver fibrosis progression in patients with chronic hepatitis C." The OBSVIRC, METAVIR, CLINIVIR, and BOSVIRC Groups. Lancet 349(9055):825-832 (March 22, 1997) |
|-------------------------|--------------|---|
| | *A16 | Teare et al., "Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis." Lancet 342:895-898 (October 9, 1993) |
| | *A17 | Wong et al., "Serum byeturonic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection." J. Viral Hepat. 5:187-192 (May 1998) |
| | | |
| | | |
| | | |
| | | |
| | | |
| Examiner | Signatu | re: 18. Such Date Considered: 21 Oceanier 2006 |
| EXAMINE citation if not | R: Initial | if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through mance and not considered. Include copy of this form with next communication to applicant. |